Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06489041 · ClinicalTrials.gov registry record · NA
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
A NA study of Cancer and Gastrointestinal Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06489041 is a NA study of Cancer and Gastrointestinal Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 120 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06489041, a NA study of Cancer and Gastrointestinal Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Conditions Studied
Interventions
- GENETIC Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
Study Locations (1)
North Carolina
- Atrium Health Levine Cancer - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06489041
The ClinicalTrials.gov registry entry for NCT06489041 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx" is the first listed.
NCT06489041 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06489041 about?
NCT06489041 is a clinical study titled "Evaluating Microarray Pharmacogenetic Testing in Cancer Patients". The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
What is the current status of trial NCT06489041?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-07-18. Estimated completion is 2026-12.
What conditions does trial NCT06489041 study?
This clinical trial studies the following conditions: Cancer, Gastrointestinal Cancer.
What interventions are being tested in trial NCT06489041?
The interventions under investigation include: Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx" (GENETIC).
Who is sponsoring clinical trial NCT06489041?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06489041 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.